Because DcR3 expression was associated with tumor differentiation, tumor infiltration depth, tumor metastasis, and lower survival, DcR3may be useful as a biomarker for making early diagnoses, predicting prognoses, and improving disease management in patients with CRC. This evidence concerns the gene TNFRSF6B and neoplasm.